ARCHIVES

FDA Approves Gemzar For Ovarian Cancer, Contradicting ODAC Recommendation; Continues Agency Trend to Recognize Progression-Free Survival As An Endpoint.

This article is from The Cancer Letter archive.

Vol. 32 No. 28 | July 21, 2006

Download PDF Visit The Full Archive

Related Articles

DCE Board Approves Concept For studies Of Thorotrast Exposure

November 16, 1990

RFAs: Patient Outcomes “5-A-Day” Program

April 10, 1992

Bush Appoints Lander To NCAB

January 24, 2003

Cancer Center In Russia Seeks Cancer Drugs, Other Supplies, From US

July 30, 1993

New CCP Lineup remains Unclear; 11 Bases OK’d

April 5, 1991

ORI Bars Cleveland Researcher From Federal Funding

March 24, 1995